logo
Share SHARE
FONT-SIZE Plus   Neg

Enzymotec Appoints Steve Dubin As Chairman

Enzymotec Ltd. (ENZY), a developer, manufacturer and marketer of innovative bio-functional lipid ingredients, announced Thursday that it has appointed Steve Dubin as Chairman of its board of directors, effective January 1, 2014.

The company also announced that it has appointed Yoav Doppelt as Vice Chairman of the board. Doppelt has served as Chairman of Enzymotec's board of directors since October 2011 and as a director since 2001. He will continue to be an actively involved board member and will assist Dubin during the transition process.

Steve Dubin has served as Vice Chairman of Enzymotec's board of directors since April 2013. Since November 2011, Dubin has been a Principal in SDA Ventures LLC.

Dubin also acts as a Senior Advisor to Paine & Partners, LLC. From 2006 until its acquisition by Royal DSM N.V. in February 2011, Dubin served as Chief Executive Officer and a member of the board of directors of Martek Biosciences Corporation. He also served as President of DSM's Nutritional Lipids Division immediately after DSM's acquisition of Martek and as a Senior Advisor to DSM Nutritional Products from 2011 through October 2012.

Having joined Martek in 1992, he held various management positions, including Chief Financial Officer, Treasurer, Secretary, General Counsel and Senior Vice President, Business Development, as well as President of Martek from 2003 to 2006.

Dubin is a co-founder and co-manager of a Maryland-based, angel-investing club. Dubin currently serves as a member of the board of several privately held companies, including The Brain Center, LLC, MyCell Technologies and its subsidiary Oceans Omega LLC, and Alcresta, Inc. Prior to that, he was a member of the board of directors of Scerene Healthcare Inc.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Shares of Philips Electronics NV were gaining around 4 percent in the early morning trading in Amsterdam after the Dutch consumer electronics giant reported Monday that its second-quarter net income from continuing operations increased with higher sales and orders. Net income, meanwhile, declined with lower income from discontinued operations. Embark Veterinary Inc., a startup that makes dog DNA-testing kits for pet owners, vets and breeders, said it has raised $4.5 million in funding from investors and relocated its headquarters to Boston. The company intends to use the new funding to expand its canine genetic testing suite for pet owners, breeders, and veterinarians. Intel Corp. has completely shut down its wearables division about two weeks ago, CNBC reported, citing a person familiar with the matter. The company reportedly intends to focus on augmented reality. According to the CNBC report, Intel laid off about 80 percent of the team that made the Basis fitness watch in November 2016 and has now eliminated the division entirely.
comments powered by Disqus
Follow RTT